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Abstract
The redefinition of neuropathic pain as “pain arising as a direct consequence of a lesion ordisease affecting the somatosensory system,”
whichwas suggestedby the International Association for theStudyof Pain (IASP) Special InterestGrouponNeuropathicPain (NeuPSIG)
in 2008, has been widely accepted. In contrast, the proposed grading system of possible, probable, and definite neuropathic pain from
2008 has been used to a lesser extent. Here, we report a citation analysis of the original NeuPSIG grading paper of 2008, followed by an
analysis of its use by an expert panel and recommendations for an improved grading system. As of February, 2015, 608 eligible articles
in Scopus cited the paper, 414 of which cited the neuropathic pain definition. Of 220 clinical studies citing the paper, 56 had used the
grading system. The percentage using the grading system increased from 5% in 2009 to 30% in 2014. Obstacles to a wider use of the
grading systemwere identified, including (1) questions about the relative significance of confirmatory tests, (2) the role of screening tools,
and (3) uncertainties about what is considered a neuroanatomically plausible pain distribution. Here, we present a revised grading
systemwith an adjusted order, better reflecting clinical practice, improvements in the specifications, and aword of caution that even the
“definite” level of neuropathic pain does not always indicate causality. In addition, we add a table illustrating the area of pain and sensory
abnormalities in common neuropathic pain conditions and propose areas for further research.
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1. Introduction
In 1994, the International Association for the Study of Pain (IASP)
defined neuropathic pain as “pain initiated or caused by a primary
lesion or dysfunction in the nervous system.” In 2008, a task force
initiated by the IASP Special Interest Group on Neuropathic Pain
(NeuPSIG) noted the need to distinguish neuropathic pain from
nociceptive pain arising indirectly from neurological disorders and
pain conditions with secondary neuroplastic changes occurring in
the nociceptive system, andproposed a newdefinition that omitted
the term “dysfunction”: “pain arising as a direct consequence of
a lesion or disease affecting the somatosensory system.”30 A
slightlymodified version of this definitionwas proposed by the IASP
TaxonomyCommittee and accepted by the IASP: “pain caused by
a lesion or disease of the somatosensory nervous system.”16,17
The omission of the term “dysfunction” excludes conditions
involving ill-defined changes in the nervous system and conditions
with no known lesion of the somatosensory nervous system from
being classified as neuropathic pain. The restriction to the
somatosensory nervous system is important because conditions
such as musculoskeletal pain (eg, due to spasticity) arising
indirectly from disorders of the motor system should not be
confused with neuropathic pain. The term “primary” was omitted
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because of the difficulty in distinguishing between primary and
secondary causes of neuropathic pain; however, the omission
means that nociceptive pain conditions that—over time—may
cause secondary lesions in the somatosensory nervous system
could ultimately be considered as being partly neuropathic pain.
Recognizing the challenges of determining the presence of
neuropathic pain according to this new definition, NeuPSIG also
proposed a grading system30 to guide decisions on the level of
certainty with which neuropathic pain can be determined in an
individual patient. Three levels of certainty—possible, probable,
and definite neuropathic pain—were proposed. As an activity in the
Global Year Against Neuropathic Pain,15 NeuPSIG established
a committee to (1) critically evaluate theuse of thegrading system in
the 7 years after its publication, (2) assess the usefulness and
limitations of the grading system, and (3) update thegrading system
if required, for improvedapplication in clinical and research settings.
The committee consisted of an expert panel of neurologists, clinical
neurophysiologists, neuroscientists, anesthesiologists, pain spe-
cialists, primary care physicians, and population health scientists.
2. Procedure
To generate background material and discussion points, we
performed a systematic literature search using the Scopus
database, which is an abstract and citation database of peer-
reviewed literature (including scientific journals, books, and confer-
ence proceedings). This database was searched on February 6,
2015 for publications that cited the original NeuPSIG grading paper
from2008.30 Three review authors (S.H., P.K., andN.B.F.) extracted
the following data: (1) use of the citation, (2) classification of the
publication as a review, animal or human experimental paper,
a clinical study, or others, (3) criteria used for including or classifying
patients with neuropathic pain in clinical studies, (4) comparison of
the grading with other criteria for identifying neuropathic pain when
available, and (5) any issues raised with the grading system.
In addition, all committee members were asked to examine the
grading system for possible deficiencies that could require
modification or amendment in a subsequent iteration of the grading
system. Participants convened under the auspices of NeuPSIG in
Nice, France, on May 14, 2015. Before the meeting, all participants
wereprovidedwith adocumentation folder that included results from
the literature review and issues identified by committeemembers. At
the meeting, data on the use of the grading paper were presented,
and individual participants provided short overviews on issues with
the grading system that had been identified before the meeting.
Discussions pertaining to the issues identified before the meeting
and new issues raised by participants at the meeting were used to
informmodifications to the existing grading system. Before and after
the meeting, the process and update were discussed through
e-mail, and after circulating draft manuscripts through e-mail, a final
update was agreed through consensus by e-mail.
3. Background material
A total of 731 publications were identified in Scopus as citing the
original grading paper30 at the time of search, which represented
about 5% of all publications in Scopus with the term “neuropathic
pain” in the title, abstract, or keywords in the same period. Of the
731 publications, 123were not available as full-text at any of the 3
institutions, at which the reviewers were based or were in
a language not understood by the reviewers. Hence, the full text
of 608 publications was downloaded and used to evaluate the
use of the original grading paper since its publication in 2008. Of
the 608 included publications, 269 were classified by the
reviewers as reviews or book chapters, 220 as clinical studies,
73 as experimental studies, and 46 as “others.”
Of the 608 publications, 414 cited the grading paper30 in
relation to the definition of neuropathic pain (Fig. 1). Of these, 266
used the definition as it was presented (or very similar) in the
original grading paper, whereas 48 applied the adapted 2011
IASP definition17 and 8 applied the 1991 IASP definition despite
using the grading paper as the reference. Ninety-two presented
other definitions of neuropathic pain, of whichmost had awording
consistent with the definition in the grading paper, whereas others
presented a definition significantly different despite using the
grading paper as reference. The grading paper was cited in
relation to other statements, unrelated to the definition or grading
system, in 190 publications.
Of the 220 clinical publications that included patients, only 56
(25% of clinical studies, 9% of all studies citing the grading paper)
used the grading system to include or classify patients as having
possible, probable, or definite neuropathic pain. A further 16 (7%)
Figure 1. Summary of how the citations of the neuropathic pain grading paper30 were used. The figure indicates the percentage of 608 publications that cited the
original grading paper30 for defining neuropathic pain and the number of clinical studies that used the grading system for identifying neuropathic pain. The insert
indicates the total number of clinical studies and the number of studies using the grading system30 for identifying neuropathic pain per year.
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used other criteria for classification of pain, but retrospectively
noted whether the patients had possible, probable, or definite
neuropathic pain according to the grading system. The percent-
age of clinical studies citing the grading system that also used it to
include or classify patients with neuropathic pain increased from
5% (1/20) in 2009 to 30% (12/40) in 2014 (Fig. 1). Of the
remaining 148 studies that did not use the grading system for
patient classification, 115 used other criteria to include or classify
neuropathic pain patients. Of these, 50 used one or more
questionnaires, 30 used Douleur Neuropathique en 4 questions,
11 used painDETECT, 8 LANSS (Leeds Assessment of Neuro-
pathic Symptoms and Signs) or S-LANSS (self-report LANSS),
2 used McGill pain questionnaire, 1 used ID-Pain, 1 used
standardized evaluation of pain, and 1 used the German pain
questionnaire; 51 used various criteria including pain history, pain
descriptors, clinical examination, and laboratory investigations; 2
used patient self-report; and 12 did not mention the criteria used.
Thus, the 2008 grading paperwasmostly cited for the redefinition
of neuropathic pain. The redefinition has since been introduced in
the IASP terminology with minor modifications, and hence the
authors’ aim “to develop a more precise definition of neuropathic
pain that will be useful for clinical and research purposes” has largely
been achieved. The adoption of the grading system has naturally
happened after a delay, and since2011a steady ratio of about 1/3 of
clinical trials in the field have used it (Fig. 1).
A meta-analysis of cancer trials4 indicated that of the 4 criteria of
the grading system, criterion 2 “a history suggestive of a relevant
lesion or disease affecting the peripheral or central somatosensory
system” and criterion 3 “demonstration of the distinct neuro-
anatomically plausible distribution by at least 1 confirmatory test”
were available in the majority of trials (13-14 of 22), whereas
criterion 1 “pain with a distinct neuroanatomically plausible
distribution” was available less often (10/22) and confirmation of
the underlying lesion of disease was rarely done (criterion 4, 7/22).
This identifies 2 problems to be addressed in the present revision:
(1) plausibility of pain distribution and its assessment and (2) need
for establishing the neurological diagnosis by confirmatory tests.
In addition, the following deficiencies were identified from the
paper reviews and discussed during the committee meeting: (1)
Several screening tools (questionnaires)were developed before the
redefinition of neuropathic pain by NeuPSIG and IASP3,13 but are
not positioned in the grading system; (2) Some clinicians and
investigators have difficulty in determining the topographical
location of a lesion and its pathology, as the approach used in
neurology of “where is the lesion?”, “what is the lesion?” is not
intuitive to other medical disciplines; (3) Certain sensory signs are
not specific to neuropathic pain; and (4) Determination of lesion
typeand locationdoes not necessarily prove that the pain is caused
by that lesion or disease (uncertainty of causal relationship).
Based on these limitations of the current grading system, we
propose a change to the order of the grading criteria to better
reflect clinical practice and have furthermore annotated the terms
used to improve clarity (Fig. 2). In addition, a research agenda is
proposed to further address shortcomings of the grading system.
Figure 2. Flow chart of updated grading system for neuropathic pain. aHistory, including pain descriptors, the presence of nonpainful sensory symptoms, and
aggravating and alleviating factors, suggestive of pain being related to a neurological lesion and not other causes such as inflammation or non-neural tissue
damage. The suspected lesion or disease is reported to be associated with neuropathic pain, including a temporal and spatial relationship representative of
the condition; includes paroxysmal pain in trigeminal neuralgia. bThe pain distribution reported by the patient is consistent with the suspected lesion or disease
(Table 1). cThe area of sensory changes may extend beyond, be within, or overlap with the area of pain. Sensory loss is generally required but touch-evoked or
thermal allodynia may be the only finding at bedside examination. Trigger phenomena in trigeminal neuralgia may be counted as sensory signs. In some cases,
sensory signs may be difficult to demonstrate although the nature of the lesion or disease is confirmed; for these cases the level “probable” continues to be
appropriate, if a diagnostic test confirms the lesion or disease of the somatosensory nervous system. dThe term “definite” in this context means “probable
neuropathic pain with confirmatory tests” because the location and nature of the lesion or disease have been confirmed to be able to explain the pain. “Definite”
neuropathic pain is a pain that is fully compatible with neuropathic pain, but it does not necessarily establish causality.
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4. Revised grading system
The grading system is intended for determining the level of
certainty with which the pain in question is neuropathic. A finding
of probable neuropathic pain in a given individual patient should
prompt consideration of treatment according to the neuropathic
pain treatment guidelines,10 but the grading system is not
intended for medico-legal purposes or to classify diseases. The
refinements in the present grading system (Fig. 2) follow the
classical clinical method of diagnosis in that history, clinical
examination, and diagnostic tests stepwise add to level of
certainty that the pain in question is neuropathic.
4.1. Possible neuropathic pain
Evaluation of thepatient according to the grading systemshould be
undertaken if the patient’s history suggests that pain could be
related to a neurological lesion or disease and not other causes
such as inflammation or non-neural tissue damage. At this stage,
pain descriptors, the presence of nonpainful sensory symptoms,
and any aggravating and alleviating factors can be taken into
account. Pain descriptions such as burning or hot, electric shocks
or shooting, pricking or pins and needles, pain evoked by light
touchingor cold, and nonpainful sensations suchas numbness and
tingling are suggestive, but not pathognomonic for neuropathic
pain, and other descriptors may apply as well.3 The combination of
several descriptors, however, has a highly discriminant value and
several screening tools (questionnaires) have been developed to
identify patientswhomay have neuropathic pain to alert the clinician
to undertake further assessment (though they cannot be used
alone to identify neuropathic pain).3,13,32 These include, but are not
limited to the LANSS,2 the neuropathic pain questionnaire,18 the
Douleur Neuropathique en 4 questions,6 the painDETECT,11 and
ID-Pain.24
The following two criteria need to be fulfilled to reach the first
level of certainty-“possible” neuropathic pain.
4.1.1. A history of relevant neurological lesion or disease
There should be a clinical suspicion of a relevant lesion or disease
of the somatosensory nervous system (eg, an episode of acute
herpes zoster or a traumatic nerve injury). The temporal relationship
between the lesion or disease and the pain may vary, but a close
temporal relationship helps strengthen the clinical suspicion. The
onset of pain is usually immediate or within a few weeks of the
lesion or disease but may be delayed for up to several months after
injury (eg, after stroke) or for many years in conditions with an
insidious onset such as diabetic neuropathy. In some cases, the
history of pain or sensory disturbances by themselves suggest
a disease, eg, in polyneuropathy (peripheral neuropathy),where the
insidious onset of distal pain or numbness may be the only history
indicating the disease. Characteristic sudden short-lasting (usually
a few seconds) paroxysmal pain in the face, which may recur
several times and may be separated by a refractory period (usually
someminutes), suggests trigeminal neuralgia, where the pain is the
only symptom indicating a relevant neurological disease.
4.1.2. Pain distribution neuroanatomically plausible
The pain distribution should be anatomically consistent with the
suspected location of the lesion or disease in the peripheral or
central somatosensory nervous system (as derived from the
patient’s history). This can be difficult to decipher in the single
patient, as the distribution of pain can occupy a smaller area or
extend somewhat outside the innervation territory of a peripheral
nerve or root or the somatotopic representation of the body within
the central nervous system, but it should be in a distribution that is
typical for the underlying disorder (see examples in Table 1). In
painful channelopathies, the pain distribution may be unusual but
should be consistent with the disorder, eg, familial episodic pain
syndrome, in which pain ismainly localized to the chest and upper
arms, or inherited erythromelalgia, in which pain is localized to the
extremities (feet and hands and in some cases ears).
When both requirements 1 and 2 of the pain history are fulfilled,
the pain complaint may be termed possible neuropathic pain.
4.2. Probable neuropathic pain
The next level of certainty requires supporting evidence obtained
by a clinical examination. The examination should optimally
confirm the presence of negative sensory signs, ie, partial or
complete loss to one or several sensory modalities concordant
with the lesion or disease of the somatosensory nervous system
(eg, light touch, cold temperature, Tables 1 and 2).
Demonstrating sensory loss to one or more of these modalities
and delineation of the area affected by the negative sensory
phenomena are central to the determination as to whether
a nervous system lesion is the cause of the sensory disturbance
(ie, whether it is compatible with neuropathy). Negative sensory
signs may also be seen in nociceptive pain, but in these cases
they lack neuroanatomically distinct borders and are not re-
producible.12,19 The sensory signs may or may not be accom-
panied by motor or autonomic signs.
Positive sensory signs alone (eg, pressure-evoked hyperalgesia)
carry less weight towards neuropathic pain probability, in
particular, if their distribution does not follow relevant neuroana-
tomical delineation. Positive sensory symptoms and signs may be
seen in patients with other conditions such as inflammatory pain,
pain of unknown origin, anxiety, and sleep deprivation, and can be
affected by stress and negative emotions.25,34 It is important to
emphasize that there are conditions where sensory loss is not
a prerequisite for a neuropathic pain condition. In certain
neuropathic pain conditions such as hereditary channelopa-
thies1,33 and in subgroups of patients with, eg, peripheral nerve
injury,20 touch-evoked allodynia or thermal hyperalgesia may be
present without detectable sensory loss. The presence of such
positive signs may mask sensory loss in some of these patients.
Idiopathic or classical trigeminal neuralgia is a special case. In
trigeminal neuralgia, sensory deficits may not be found on clinical
examination, although quantitative sensory testing may show
sensory abnormality.20 In these cases, a history of characteristic
triggering maneuvers may be counted as positive sensory signs.
They can sometimes be repeated by the examiner, whomay thus
evoke and see the characteristic tic. Another special case is
painful channelopathies as they are often paroxysmal and
sensory examination can be normal between attacks. A history
of characteristic symptoms may be considered a surrogate for
positive sensory signs. In phantom pain, a sensory examination is
not possible in the pain area. In these cases, the loss of the body
part where pain is perceived is counted as a surrogate for sensory
signs within the pain distribution.
Often, sensory changes to light touch, vibration, pinprick, cold,
or warmth can be confirmed by a clinical examination (Table 2),
but more detailed analysis using quantitative sensory testing may
be needed.13 Prolonged pain after herpes zoster is associated
with sensory abnormalities in a neuroanatomically plausible
distribution in most, but not all cases.20 In rare cases where
sensory abnormalities are doubtful or lacking, documentation of
a herpes zoster rash in the form of a photograph or clinical record
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will add to the evidence of somatosensory pathway involvement,
allowing a subsequent designation of the condition as probable
neuropathic pain. Sensory function is difficult to evaluate in deep
tissue and viscera. For that reason, a level of certainty beyond
possible neuropathic pain can rarely be obtained for visceral or
deep somatic types of pain. Innervation territories of nerves and
roots vary between individuals, they are not always clearly
demarcated, and there is often overlap between them. Because
of central sensitization phenomena, the areas of allodynia and
hyperalgesia may extend beyond the innervation territory.35
Table 1
Common neuropathic pain conditions and neuroanatomically plausible distribution of pain symptoms and sensory signs.
Neuropathic pain condition Neuroanatomically plausible distribution of
pain and sensory signs
Illustration of typical distribution
Trigeminal neuralgia Within the facial or intraoral trigeminal territory.
Postherpetic neuralgia Unilateral distributed in one or more spinal
dermatomes or the trigeminal ophthalmic division.
Peripheral nerve injury pain In the innervation territory of the lesioned nerve,
typically distal to a trauma, surgery, or
compression.
Postamputation pain In the missing body part and/or in the residual limb.
Painful polyneuropathy In feet, may extend to involve lower legs, thighs, and
hands.
Painful radiculopathy Distribution consistent with the innervation territory
of the nerve root.
Neuropathic pain associated with spinal cord
injury
At and/or below the level of the spinal cord lesion.
Central poststroke pain Contralateral to the stroke. In lateral medullary
infarction, the distribution can also involve the
ipsilateral side of the face.
Central neuropathic pain associated with
multiple sclerosis
Can be a combination of distributions seen in spinal
cord injury and stroke.
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4.3. Definite neuropathic pain
The final level of certainty requires that an objective diagnostic test
confirms the lesion or disease of the somatosensory nervous
system. This may not always be possible in the nonspecialist
environment. Examples of such diagnostic tests include com-
puted tomography, magnetic resonance imaging, or other
imaging techniques to confirm the presence of stroke, multiple
sclerosis, spinal cord injury, or nerve lesion; skin biopsy showing
reduced intraepidermal nerve fiber density, neurophysiological
tests such as nerve conduction velocity, heat and laser evoked
potentials, nerve excitability tests, R1 blink reflex demonstrating
neural function compromise, microneurography with evidence of
aberrant nociceptor activity; and genetic tests confirming
a hereditary neuropathic pain disorder such as inherited
erythromelalgia.13 In cases of amputation or a surgeon’s clear
verification of an intraoperative nerve lesion, further diagnostic
tests are not necessary to arrive at the grading of “definite”
neuropathic pain, because direct anatomical or surgical evidence
counts as a confirmatory test.
This final level is reached by using only positive criteria for the
location and nature of the neurological lesion or disease, without
excluding other potential causes of the pain. Patients can have
nociceptive pain in an area within the territory affected by an injury
or disease involving the nervous system. Examples include
spasticity-related pain below the level of injury in a patient with
incomplete spinal cord injury, shoulder pain because of a lesion of
the rotator cuff tendons in the area with sensory abnormalities
after a stroke, inflammatory pain in the innervation territory of the
lesioned nerves after thoracotomy or herniotomy, and plantar
fasciitis in a patient with polyneuropathy. In these cases, despite
fulfilling all 4 criteria of the grading system, the painmay still not be
neuropathic. Thus, it is important to note that the final level does
not completely rule out the possibility that other conditions such
as tissue inflammation may fully or partially explain the pain. This
remaining uncertainty about causality between the identified
lesion or disease and the clinical presentation of the patient is
a common situation in neurological diagnostics. In this context,
the term definite neuropathic pain means that the clinician, by
using history, clinical examination and auxiliary testing, is able to
reach the level of confirming clinically that a patient has
a neurological lesion that can explain the pain. Because the
grading system only determines the level of certainty with which
the presence or absence of a lesion or disease of the
somatosensory nervous system can explain the pain, it is always
important to consider if other causes for the patient’s pain
conditions may be present.
4.4. Summary
Compared to the grading system published in 2008, we have
(1) changed the order of the grading criteria to better reflect
clinical practice.
(2) annotated the terms used to improve clarity.
(3) recognized the role of screening tools (questionnaires) in
neuropathic pain evaluation.
(4) emphasized that reaching the final level of certainty (definite
neuropathic pain) confirms clinically that a lesion or disease of
the somatosensory nervous system can explain the pain but,
as often in neurology, it does not establish causality (ie, there
may still be other causes of the pain such as a diabetic ulcer).
The main purpose of the grading system is to help in the
classification of the pain as neuropathic. Other types of pain
include nociceptive pain, which is pain that arises from actual or
threatened damage to non-neural tissue and is due to the
activation of nociceptors,16 and pain that does not fulfill the
criteria for either nociceptive or neuropathic pain, such as chronic
widespread pain, fibromyalgia, and irritable bowel syndrome.31
Furthermore, patients may have 2 or more types of pain, and the
classification of pain may be particularly difficult if more than one
type of pain exist in the same area.
The grading system is intended for use in individual patients in
the clinic and for research, but not for classification of diseases.
Some patients diagnosed with fibromyalgia may have small fiber
pathology and may fulfill the criteria for neuropathic pain whereas
others may not.9,26 In addition, patients with complex regional
pain syndrome (CRPS) type II fulfill the criteria for neuropathic
pain, whereas patients with type I do not. Complex regional pain
syndrome type I is by definition a condition in which no nerve
lesion can be verified.5 Although an inflammatory reaction,
considered to be at the core of development of CRPS, can
conceivably damage nociceptors, the current pathophysiological
evidence for it is limited and inconsistent, and thus does not justify
the designation by default of CRPS type I as neuropathic pain.7,23
Similarly, individual patients with Parkinson’s disease may have
neuropathic pain if there is a documented lesion of the
somatosensory system and they fulfill the grading criteria, but
musculoskeletal pain is an important differential diagnosis. The
demonstration of reduced small nerve fibers obtained from skin
biopsies in patients with fibromyalgia and Parkinson’s disease is
at the moment not sufficient evidence per se for labeling pain in
these patients as neuropathic. There is currently no evidence to
indicate that patients with cluster headache or migraine have
lesions of the somatosensory system.
5. Limitations and future directions
Based on the narrative literature review and discussions in the
committee, we identified several weaknesses in our current
knowledge about neuropathic pain and issues that need to be
addressed in the future.
(1) The lack of positive criteria for identifying non-neuropathic
pain, and the lack of pathognomonic features of neuropathic
pain make it difficult to reach a level of “definite” neuropathic
pain. Previous attempts to define a gold standard for
neuropathic pain have been hampered by the inherent circular
bias imposed by the fact that the criteria for defining clinical
neuropathic pain are also used as measures in newly
introduced tools. One important area of research will be to
use the present grading system as a reference standard
against which other neuropathic pain approaches should be
systematically validated. In this goal, it will be important to
perform field testing of this system, in particular, to assess its
test-retest reliability and inter-rater reliability.
(2) The lack of pain diagnostic tools for low resource settings and
the need for more educational efforts.22 Screening tools may
be helpful, but at a single-patient level, they may wrongly
Table 2
Bedside sensory examination.
Modality Bedside assessment
Touch Cotton bud or ball, painter’s brush
Vibration Tuning fork
Pinprick Pin, toothpick, cocktail stick
Cold Cold metal, tube with cold water, cloth with surgical
spirit, Lindblom roller21
Warm Warm metal, tube with warm water, Lindblom
roller21
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classify some patients (false-positive) or fail to identify other
patients (false-negative).3,32
(3) In research based only on clinical history, such as question-
naire surveys and patient interviews, only the level of “possible”
neuropathic pain can be reached and even then only
sometimes. Although validated questionnaires exist, these
questionnaires were mostly developed based on the old and
less precise IASP definition, and there is no validated approach
to defining relevant pain distribution and history.29
(4) Variability of innervation territories of roots, nerves and
fascicles as well as difficulty in quantitating sensory function
in deep tissues such as joints and muscles and visceral tissues
can make it difficult to identify neuropathic pain in certain
cases, and current textbook figures are based on often
imprecise renditions of very old data from relatively small case
series. In future, it is important to generate probabilistic maps of
innervation territories and to develop methods for the
assessment of sensory function in joints and muscles and
visceral tissues. Identification of appropriate control areas for
specific conditions, establishment of inter- and intra-examiner
reliability, and assessment of the use of patient self-examina-
tion14,27 are also needed.
(5) The possible presence of neuropathic pain in conditionswhere
lesions or diseases of the somatosensory nervous system
occur secondary to an inflammatory condition is not clear.
Examples are osteoarthritis, in which there may be a decrease
in the innervations in the synovial lining layer and increase in the
innervations of cartilage with concomitant sensory abnormal-
ities in the skin,28 and chronic pancreatitis, in which histopa-
thology shows evidence of local nerve involvement.8
6. Conclusions
Neuropathic pain is a term used for a group of conditions with
a wide range of causes and different pain distributions. However,
all these conditions are characterized by a lesion or disease
affecting the somatosensory nervous system peripherally or
centrally. The grading system represents a tool to determine the
level of certainty that the pain in an individual is neuropathic in
nature. Such grading is naturally based on clinical judgment.
Therefore, it relies heavily on the experience, skills, and resources
available for assessment.
We anticipate that the rephrasing and reordering of the 4
criteria of the grading system will facilitate its use by both
neurologists and non-neurologists. The level “probable” should
usually be sufficient to initiate treatment according to neuropathic
pain guidelines. The level “definite” is useful in specialist contexts
and when a causal treatment of the underlying lesion or disease is
an option. In some cases, sensory signs in the painful areamay be
difficult to demonstrate, although the nature of the lesion or
disease is confirmed (eg, trigeminal neuralgia, channelopathies,
postherpetic neuralgia); for these cases, the level “probable”
continues to be appropriate if a diagnostic test confirms the lesion
or disease of the somatosensory nervous system.
This paper includes an update of the grading system published
in 2008.30 The goal of this update is to provide a revised grading
system that is clinically useful, internally consistent, and allows
appropriate treatment decisions in the face of uncertainty. We
anticipate that the revised grading system will be incorporated
into the “content model” of neuropathic pain in the upcoming
11th version of the International Classification of Diseases.31 We
have also identified a range of important research topics that will
further improve the classification and grading of neuropathic pain
in the future.
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